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Introduction
Th  e year 2009 was again an interesting one for readers 
interested in the ﬁ  eld of infection in critically ill patients. 
Several promising new approaches for the prevention of 
infections in the intensive care unit (ICU) setting were 
presented. Furthermore, progress was noted in the diﬃ   -
cult area of antimicrobial stewardship and risk stratiﬁ  -
cation of infected patients. Finally, several challenges 
related to inﬂ  uenza infections and the management of 
diﬃ     cult-to-treat infections were tackled or better 
delineated [1]. Th   e present short review will summarise 
the results of a selection of original studies, with a special 
focus on articles published in Critical Care in 2009.
Epidemiology of infection in critically ill patients
New insights were reported regarding the epidemiology 
of infection in ICUs. A global, observational study 
(EPIC II) on the prevalence and outcomes of infection in 
1,265 ICUs was conducted in 75 countries in May 2007. 
Among the 13,796 patients, 9,084 (66%) patients received 
an antimicrobial agent and 7,087 (51%) patients were 
considered infected at the time of data collection [2]. 
Unfortunately, owing to methodological limitations, no 
clear-cut distinction could be made between community-
associated and healthcare-associated infec  tions. Among 
those patients who had stayed longer than 7 days in the 
ICU prior to the study day, however, more than 70% were 
infected, mostly with multidrug-resistant organisms 
(MDROs). A clear association was noted between preva-
lence of infection and hospital mortality, with Greece and 
Turkey having the highest mortality and Switzerland the 
lowest [2].
Since this type of prevalence study does not allow one 
to draw any strong causal inferences between infection 
rates and excess mortality due to ICU-acquired infec-
tions, longitudinal cohort studies with more sophisticated 
analyses have to be conducted. For instance, a recent 
French ICU-based case–control study matched 1,725 
deceased patients with 1,725 surviving control patients to 
determine the excess mortality related to ICU-acquired 
infection [3]. Th  e adjusted population-attributable frac-
tion of deaths due to ICU-acquired infection for patients 
who died before their ICU discharge was 14.6% (95% 
conﬁ  dence interval (CI) = 14.4 to 14.8). Th  e  attributable 
mortality of ventilator-associated pneumonia (VAP) was 
6.1% (95% CI = 5.7 to 6.5), an estimate close to the 8.1% 
(95% CI = 3.1 to 13.1%) provided by a multistate model of 
another cohort study that appropriately handled VAP as 
a time-dependent event [4].
VAP is a serious complication after major heart surgery 
in many parts of the world; however, its prevalence and 
epidemiology varies considerably from hospital to hospital 
[5,6]. In a recent pan-European cohort study con  ducted in 
25 hospitals in eight diﬀ  erent European coun  tries, one or 
more nosocomial infections were detected in 43 (4.4%) 
patients. VAP was the most frequent nosocomial infection 
(2.1%; 13.9 episodes per 1,000 days of mechanical 
ventilation) [6]. Overall, this rate of VAP is relatively high 
compared with other surveillance data [7] and warrants 
further preventive eﬀ  orts, as described below.
Prevention of ventilator-associated pneumonia
In many ICUs there is an urgent need to improve 
adherence to already established infection control 
measures designed to minimise the risk and rates of VAP. 
Technology-driven, costly or risky approaches such as 
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tamination should not be implemented as standard of 
care for all patients [8,9]. Instead, high priority should be 
given to improving routine hand hygiene, as well as to 
other routine preventive measures such as backrest 
elevation >30°, correct cuﬀ  -pressure maintenance, avoid-
ance of gastric overdistension and nonessential tracheal 
suction, and good oral hygiene, which is probably one of 
the most important and easy-to-perform interventions to 
successfully prevent VAP [10].
Th  e use of chlorhexidine-based oral rinses could be 
particularly helpful in preventing endogenous and 
exogenous contamination of patients’ upper and lower 
airways by decreasing the bacterial load present in the 
oropharyngeal ﬂ   ora [11]. Scannapieco and colleagues 
conducted a randomised, double-blind, placebo-
controlled clinical trial of chlorhexidine gluconate on oral 
bacterial pathogens in mechanically ventilated patients 
[12]. While 175 subjects were randomised, full follow-up 
assessment after at least 48 hours of ICU stay was only 
available for 115 patients. Chlorhexidine reduced the 
number of Staphylococcus aureus, but not the total 
number of Enterobacteriacae, Pseudomonas spp. or 
Acinetobacter spp. in the dental plaque of included 
subjects. A nonsigniﬁ  cant reduction in VAP rates was 
noted in groups treated with chlorhexidine compared 
with the placebo group (odds ratio = 0.54, 95% CI = 0.23 
to 1.25). A similar study conducted in Spain investigating 
the eﬀ   ectiveness of oral rinses with chlorhexidine in 
preventing nosocomial respiratory tract infections 
among ICU patients also failed to demonstrate a 
signiﬁ  cant eﬀ  ect [13]. It remains to be elucidated whether 
the limited power or other methodological issues related 
to these studies could explain the negative study results 
[14,15].
Chlorhexidine-based infection control measures
Several recently published high-quality studies have 
highlighted the potential beneﬁ  t of using chlorhexidine 
for the prevention of catheter-related bloodstream 
infections. A prospective randomised trial was performed 
in seven ICUs of ﬁ  ve French hospitals to assess the eﬀ  ect 
of two preventive practices on catheter-related blood-
stream infection rates: frequency of dressing change (3 
days vs. 7 days) and type of dressing (standard vs. 
chlorhexidine-impregnated sponges) [16]. Th  e use of 
chlorhexidine-impregnated sponges decreased the rate of 
catheter-related bloodstream infection from an already 
low level of 1.3 to 0.4 episodes per 1,000 catheter-days 
without an increase in chlorhexidine-resistant micro-
organisms. Changing catheter dressings every 7 days was 
not inferior to changing dressings every 3 days in terms 
of rate of colonisation [16]. Two studies conducted in the 
USA suggested that routine chlorhexidine body washes 
may also help to reduce catheter-related bloodstream 
infection rates in diﬀ  erent settings [17,18].
Chlorhexidine body washes have now become the 
standard of care in many ICUs to reduce the bacterial 
load on patients’ skin. A British team of investigators 
examined the impact of several control interventions 
aimed at reducing cross-transmission of methicillin-
resistant  S. aureus [19]. An educational campaign and 
cohorting had little impact on methicillin-resistant 
S. aureus transmission. Th   e introduction of chlorhexidine 
as a skin antiseptic reduced methicillin-resistant 
S.  aureus transmission of all but one of the strains 
prevalent in this ICU: the TW strain that carries the 
qacA/B genes that code for chlorhexidine resistance [19]. 
Owing to its chlorhexidine resistance, the acquisition of 
this methicillin-resistant S. aureus strain increased 
dramati  cally during the period of this interrupted time-
series study. Th  e emergence of resistance has also been 
ob  served with other topical decontamination regimens; it 
is therefore important to actively look for emerging 
chlorhexidine resistance in settings with widespread 
chlorhexidine usage [20].
Management of severe and diffi   cult-to-treat 
infections
Treatment of VAP caused by MDROs has been limited by 
the poor diﬀ  usion of certain intravenous antibiotics (for 
example, aminoglycosides) into the alveolar compart-
ment of the lungs. An elegant solution to this challenge 
could consist of the aerosolisation of antibiotic agents 
with special methods and devices [21]. In a recent pilot 
study, French investigators showed that a new mode of 
delivery of aerosolised amikacin achieved very high drug 
concentrations in the lung, while maintaining safe serum 
levels in 28 mechanically ventilated patients with Gram-
negative VAP treated for 7 to 14 days, adjunctive to 
intravenous therapy [22]. Despite these recent promising 
ﬁ  ndings, the widespread use of aerosolised antibiotics to 
treat VAP cannot be recommended at present and should 
be restricted to the treatment of multidrug-resistant 
Gram-negative VAP, as pointed out by the same group of 
investigators in a recent review [21].
Th   e management of postoperative peritonitis caused by 
MDROs may also represent a clinical challenge [23,24]. 
Augustin and colleagues determined risk factors for the 
presence of MDROs in postoperative peritonitis in 100 
patients, as well as optimal empirical antibiotic therapy 
choices among diﬀ  erent, commonly suggested treatment 
options [25]. Adequate empirical therapy was achieved in 
only 64% of cases. Adequacy decreased signiﬁ  cantly in 
patients with MDROs, as compared with patients 
presenting other bacteria (39% vs. 81%, P <0.0001). 
However, as also observed in another recent article on 
staphylococcal bacteremia [26], mortality in the study by 
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who received adequate empiric therapy and those who 
did not (30% vs. 31%), or between patients with 
peritonitis caused by MDROs and other bacteria (29% for 
MDRO group vs. 35% for others). Importantly, the 
deﬁ  nition of adequacy in this study was based purely on 
microbiological criteria and did not take yeasts into 
account. Th   e single antibiotics providing the best activity 
rate were imipenem/cilastatin and piperacillin/tazo-
bactam. Th  e best adequacy for empiric therapy was 
obtained by combinations of imipenem/cilastatin or 
piperacillin/tazobactam, amikacin and a glycopeptide 
[25]. Th  is  ﬁ  nding is in line with two recent studies from 
2010 on the use of antibiotic combinations. Both studies 
recommend antibiotic combination therapy over mono-
therapy for the initial empiric treatment phase of the 
most severely ill patients with septic shock [27,28].
Antifungal therapy has been revolutionised within the 
past 10 years. New treatment options and indications 
have continuously entered critical care and have 
increased the competition and marketing pressure. In 
this overheated area of medicine with continuous inﬂ  ux 
of new products and industry-sponsored clinical studies 
[29], it remains rather diﬃ   cult for the nonexpert critical 
care physician to evaluate true progress and the eﬀ  ective-
ness of diﬀ  erent antifungal agents in daily clinical practice, 
including the toxicity proﬁ  le of older agents [30].
Marriott and colleagues [31] undertook a nationwide 
prospective clinical and microbiological cohort study of 
all episodes of ICU-acquired candidaemia occurring in 
non-neutropenic adults in Australian ICUs between 2001 
and 2004 [32]. Overall, 183 patients had ICU-acquired 
candidaemia with a 30-day case-fatality rate of 56%. Host 
factors (older age, mechanical venti  lation and ICU 
admission diagnosis) and failure to receive systemic 
antifungal therapy were signiﬁ  cantly  associated  with 
mortality on multivariate analysis. Process of care 
measures advocated in recent guidelines were imple-
mented inconsistently: follow-up blood cultures were 
obtained in 68% of patients, central venous catheters 
were removed within 5 days in 80% of patients and 
ophthalmological examination was performed in 36% of 
patients. Th   is study showed that crude mortality remains 
high in Australian ICU patients with candi  daemia. 
Among those who were treated, mortality was over-
whelmingly related to host factors but not treatment 
variables (the time to initiation of anti  fungals or ﬂ  ucona-
zole pharmacokinetic and pharmaco  dynamic factors) 
[31].
Zilberberg and colleagues investigated the cost-
eﬀ   ective  ness of a new echinocandin antifungal agent 
(micafungin) as an alternative to ﬂ   uconazole in the 
empirical treatment of suspected ICU-acquired candi-
daemia among septic patients in a simulation model [33]. 
In the base case analysis, the authors assumed a high 
attributable mortality of ICU-acquired candidaemia 
(40%) and an overly optimistic risk reduction (52%) in 
mortality with appropriate timely therapy. Of note, in the 
Australian cohort study cited above, antifungal therapy 
was commonly started among treated patients >48 hours 
after drawing the ﬁ  rst positive blood culture; this delay 
was not associated with increased mortality [31]. 
Moreover, the model assumptions were mainly based on 
the North-American epidemiology of azole-resistant 
Candida spp. infections. Compared with ﬂ  uconazole 
(total deaths 31), treatment with micafungin (total deaths 
27) would result in four fewer deaths at an incremental 
cost per death averted of $61,446, leading to an 
incremental cost-eﬀ  ectiveness of the echinocandin over 
ﬂ  uconazole of $34,734 (95% CI = $26,312 to $49,209) per 
quality-adjusted life year.
Th  is cost-eﬀ  ectiveness analysis has severe limitations, 
since the methodology used is deﬁ  cient both in terms of 
the modelling strategy as well as the reliability of the 
probability estimates. Th   e authors used an oversimpliﬁ  ed 
approach and, sometimes, questionable probability 
estimates, result  ing in biasing their analysis in favour of 
the intervention (providing empiric anti-Candida 
therapy) and in favour of micafungin versus ﬂ  uconazole. 
Although empiric micafungin may well be an attractive 
treatment strategy, the deﬁ   ciencies in this analysis 
preclude its widespread use. Th   is study therefore should 
only represent the starting point for further investigations 
of the cost-eﬀ  ectiveness of diﬀ  erent treatment strategies 
of suspected and conﬁ   rmed fungal infections in the 
critical care setting.
Antibiotic stewardship and risk prediction
At the current time, procalcitonin (PCT) represents the 
best studied biomarker for guiding antibiotic treatment 
duration in the hospital setting [34,35]. Several high-
quality clinical trials investigating the diagnostic perfor-
mance and clinical eﬀ   ectiveness of PCT have been 
published within the past 3 years [36-39]. Two large-scale 
studies conﬁ   rmed the potential usefulness of PCT to 
guide antibiotic use in critically ill patients [37,39]. 
Nevertheless, in the study by Bouadma and colleagues 
more than one-half (53%) of patients enrolled in the 
PCT-guided arm did not follow the protocol for initial 
antibiotic treatment decisions – and thus antimicrobial 
use was not completely determined by PCT levels, as 
recommended [39]. PCT in critically ill patients therefore 
probably remains a suboptimal marker to strongly 
inﬂ  uence initial treatment decisions or even to withhold 
empiric therapy for potentially life-threatening infec-
tions. PCT measure  ments may, however, increase the 
conﬁ   dence of clinicians to withdraw antimicrobial 
therapy at an earlier timepoint in the majority of patients.
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days of sepsis in relation to adequacy of antibiotic 
therapy, Charles and colleagues conducted an 
obser  vational cohort study in 180 septic patients [40]. 
Appro  priate initial antibiotic therapy was associated with 
a signiﬁ  cantly greater decrease in PCT until day 3. Th  e 
Table 1. Comparison of community-acquired pneumonia risk scores for the prediction of intensive care unit treatment
   REA-ICU  indexa SMART-COPb  IDSA/ATS prediction rulec SCAPd
Outcome  ICU transfer within 3 days   Need for intensive respiratory  ICU admission  Mechanical ventilation, 
    of hospital admission  or vasopressor support    septic shock, or 
       in-hospital  death
Study inclusion criteria  Adult patients with CAP   Adult patients hospitalised  Patients aged >15 years  Adult patients with CAP
    without respiratory failure   with CAP  hospitalised for >12 hours  visiting the emergency
    or shock at the time of     with CAP  department (including
    hospitalisation    patients  with  expected 
       terminal  event)
Study exclusion criteria  Nursing home residents  Hospitalisation within the   Immunosuppression  Immunosuppression
      preceding 14 days, 
     immunosuppression,  receipt 
      of parenteral antibiotics prior 
      to obtainment of blood 
      samples for culture, aspiration 
      pneumonitis, withdrawal of 
      active treatment within 
      12 hours because of a poor 
     prognosis,  pregnancy
Number of criteria  11  8  11 (2 major, 9 minor)  8 (2 major, 6 minor)
Variable underlying the criteria      
 Respiratory  rate  •  •  •  •
 Heart  rate  •  •  
  Systolic blood pressure    •  •  •
e
  Septic shock with need 
 for  vasopressors      •
e 
 Body  temperature      • 
 Confusion/altered 
 mental  status    •  •  •
 Invasive  mechanical 
 ventilation      •
e 
 Multilobar  infi   ltrate  •  •  •  •
 Oxygenation  •  •  •  •
 Arterial  pH  •  •  •
e
  Blood urea nitrogen  •  •  •
 Albumin  level    •  
 Sodium  •   
  White blood cell count  •  • 
 Platelet  count      • 
 Age  •   •
 Gender  •   
 Co-morbid  conditions  •   
Sensitivity  14% (10 to 19)g  92% (85 to 97)g  71% (66 to 76)f 92%g
Specifi  city  97% (96 to 97)g  62% (59 to 66)g  88% (87 to 88)f 74%g
Area under ROC curve in 
derivation cohort  0.81 (0.78 to 0.83)g  0.87 (0.83 to 0.91)g Not  reported  0.83g
CAP, community-acquired pneumonia; ICU, intensive care unit; ROC, receiver operating characteristic. aRenaud and colleagues [PMID 19358736] [46]. bCharles and 
colleagues [PMID 18558884] [44]. cLiapikou and colleagues [PMID 19140759] [45]. dEspaña and colleagues [PMID 16973986] [43]. eMajor criterion. fValues apply to 
validation cohort. gValues apply to derivation cohort.
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day  3 higher PCT levels were measured in the non-
survivors when compared with the survivors. Th   is is the 
ﬁ  rst study to demonstrate that the PCT dynamics within 
72 hours after onset of sepsis may be correlated both with 
appropriateness of the empirical antibiotic therapy and 
with overall survival. Whether this interesting obser  va-
tion can be incorporated into clinical management guide-
lines needs to be further evaluated.
Another marker of inﬂ   ammation, C-reactive protein 
remains widely used throughout the world for diagnosis 
of infectious conditions – despite its rather limited 
diagnostic accuracy when used as a single measurement 
in time [41]. Paran and colleagues therefore investigated 
the dynamic nature of C-reactive protein in a cohort of 
patients admitted to an emergency department in Israel 
[42]. Th  ey constructed a new index, C-reactive protein 
velocity, which was deﬁ   ned as the ratio of C-reactive 
protein on admission to the number of hours since the 
onset of fever. Th   e C-reactive protein velocity improved 
diﬀ   eren  tiation between febrile bacterial infections and 
non  bacterial febrile illnesses compared with C-reactive 
protein alone. If conﬁ  rmed by other groups, this approach 
could provide clinicians with a valuable tool for estab  lish-
ing the correct diagnosis and better identifying individuals 
who need prompt therapeutic interventions [42].
Community-acquired pneumonia risk stratifi  cation
Th   e severity of community-acquired pneumonia may be 
diﬃ   cult to judge clinically. As a consequence, multiple 
scores have been proposed with the aim of predicting the 
risk of adverse outcomes in critically ill patients [43-45]. 
None of the existing rules is ideal; weaknesses include 
low sensitivity or speciﬁ   city, excessive complexity, 
underestimation of severity in younger patients, and poor 
prediction of ICU admission.
In view of both the high cost and potential beneﬁ  t of 
critical care, there is a need for tools that help ensure 
timely ICU admission for all patients with pneumonia for 
whom this is likely to improve outcome. Th  e REA-ICU 
index developed by Renaud and colleagues aims to pre-
emptively identify patients at risk of requiring secondary 
transfer to ICU within the ﬁ  rst 3 days of their hospital 
admission [46]. Th  e prediction rule was derived from a 
cohort of 4,593 patients initially presenting without overt 
circulatory or respiratory failure and was based on 11 
criteria. Nursing home residents were excluded. Th  e 
highest risk class was assigned to 3.6% of evaluated 
patients; among this group, the rate of ICU transfer 
within 3 days of admission was around 30%.
Do we need yet another community-acquired pneu-
monia severity score? Th   e merit of the study by Renaud 
and colleagues is its focus on patients who are at high risk 
despite not being obvious ICU candidates on admission. 
Th  e REA-ICU index may not, however, constitute a 
major advance in the overall endeavour of identifying 
those patients who will or should beneﬁ  t from critical 
care [47]. Compared with existing prediction rules, the 
REA-ICU index is neither less complex nor does it appear 
to be clearly superior in guiding patient management 
(Table 1). A head-to-head validation of the existing scores 
in a prospective study with separation of evaluators and 
clinical decision-makers would be desirable to better 
judge their utility in clinical practice.
H1N1 infl  uenza A
Th  e  inﬂ  uenza A (H1N1) pandemic was certainly the most 
featured infectious disease in 2009. Several highly 
accessed contributions were published in Critical Care 
during this year. Rello and Pop-Vicas highlighted the 
clinical challenges associated with primary inﬂ  uenza 
pneumonia [48]. Inﬂ  uenza A (H1N1) illness severity and 
the case-fatality rate were described in an interesting case 
series of 32 relatively young patients (median, 36 years) 
hospitalised in Spain between 23 June and 31 July 2009 
[49]. Twenty-four patients (75%) developed multiorgan 
dysfunction, and eight patients died. As conﬁ  rmed by 
later cohort studies from Australia and the UK [50,51], 
pulmonary compli  cations of inﬂ  uenza A (H1N1) infec-
tion in pregnant and young obese but previously healthy 
persons were associated with adverse health outcomes. 
Th  e same Spanish group investigated the host immune 
response following infection with inﬂ   uenza A (H1N1) 
[52]. Interestingly, severe H1N1 disease with respiratory 
involvement was characterised by early secretion of 
speciﬁ  c cytokines usually associated with cell-mediated 
immunity but also commonly linked to the pathogenesis 
of inﬂ  ammatory diseases.
Conclusions
Infection remains one of the key challenges of critical 
care and signiﬁ   cantly contributes to morbidity and 
mortality. Papers published in recent months remind us 
that further reductions of nosocomial infection rates are 
possible – often with the help of simple interventions. 
Antimicrobial resistance is a permanent threat for ICU 
patients and there is growing awareness that available 
antimicrobial agents should be used wisely. Biomarkers 
of infection can help to make more appropriate treatment 
decisions. Th  e rapid proliferation of published research 
data entails a need for consolidation of existing 
knowledge as exempliﬁ   ed by the growing number of 
community-acquired pneumonia severity scores. Clearly, 
infections in the ICU continue to be an exciting and 
important topic for ongoing research.
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